HS235 vs Sotatercept
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: Activin receptor type IIA (ActRIIA) · full Pulmonary Arterial Hypertension pipeline
HS235
Developed by GlaxoSmithKline and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2028 · NCT07143448 (registry estimate)
No aligned efficacy figure on record for this race.
Sotatercept · Winrevair
Marketed by Merck & Co. and partners
NCT04576988 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 323 treated participants and a clinical primary efficacy endpoint. The primary 6-minute walk distance comparison favored sotatercept and was statistically significant (p<0.001), supporting a strong evidence grade.
Next expected readout: August 2027 · NCT07356778 (registry estimate)
Reported efficacy
Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24); Number of Participants Who Experienced an Adverse Event (AE) (Up to approximately 24 weeks); Number of Participants Who Discontinued Study Treatment Due to an AE (Up to approximately 24 weeks): Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5) (met)
Result source: NCT04576988
Results for Pulmonary Arterial Hypertension
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
HS235: no structured comparison results are available for Pulmonary Arterial Hypertension.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Sotatercept
show 3 more results
show 1 more result
show 3 more results
+ 25 further endpoints in the CSV export.
Available safety results
Sotatercept
| Dropout rate | 2.5%Sotatercept Plus Background PAH Th NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3 show 14 more results—Sotatercept Plus Background PAH Th NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3 —Sotatercept Plus Background PAH Th NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3 19.8% NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 —Sotatercept - Extension Treatment NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 —Sotatercept - Primary Treatment Pe NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 4.8% NCT03738150 · Phase 2 · registry result, not featured evidence —0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence 14.3%0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence 3.1%0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 0.6%Sotatercept Plus Background PAH Th NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3 show 14 more results—Sotatercept Plus Background PAH Th NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3 —Sotatercept Plus Background PAH Th NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3 1.2% NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 —Sotatercept - Extension Treatment NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 —Sotatercept - Primary Treatment Pe NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 — NCT03738150 · Phase 2 · registry result, not featured evidence —0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence 9.5%0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence 3.1%0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —Sotatercept Plus Background PAH Th NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3 show 14 more results14.1%Sotatercept Plus Background PAH Th NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3 16.5%Sotatercept Plus Background PAH Th NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3 60.5% NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 4.4%Sotatercept - Extension Treatment NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 13%Sotatercept - Primary Treatment Pe NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 — NCT03738150 · Phase 2 · registry result, not featured evidence 23.8%0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence 26.7%0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence 33.3%0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.7 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence 6.3%0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence 40%0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence 32.3%0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence —0.3 mg/kg NCT03496207 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | headache 20.2% (placebo 15%) covid-19 14.7% (placebo 11.9%) diarrhoea 12.3% (placebo 7.5%) NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3 show 10 more resultsepistaxis 15.8% (placebo 1.9%) covid-19 15.2% (placebo 11.9%) telangiectasia 7.6% (placebo 3.1%) NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3 epistaxis 45.3% (placebo 7%) headache 26.7% (placebo 25.6%) diarrhoea 25.6% (placebo 17.4%) NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 nasopharyngitis 15.6% epistaxis 11.1% haemoglobin increased 6.7% NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 nasopharyngitis 30.4% headache 21.7% epistaxis 17.4% NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 0.7 mg/kg haemoglobin increased 16.7% (placebo 0%) diarrhoea 14.3% (placebo 15.6%) headache 14.3% (placebo 18.8%) NCT03496207 · Phase 2 · registry result, not featured evidence 0.7 mg/kg headache 46.7% (placebo 18.8%) nasopharyngitis 40% (placebo 9.4%) oedema peripheral 40% (placebo 15.6%) NCT03496207 · Phase 2 · registry result, not featured evidence 0.7 mg/kg oedema peripheral 19.4% (placebo 15.6%) telangiectasia 19.4% (placebo 0%) headache 16.7% (placebo 18.8%) NCT03496207 · Phase 2 · registry result, not featured evidence 0.3 mg/kg headache 25% (placebo 18.8%) diarrhoea 21.9% (placebo 15.6%) dizziness 15.6% (placebo 9.4%) NCT03496207 · Phase 2 · registry result, not featured evidence 0.3 mg/kg fatigue 40% (placebo 18.8%) nasopharyngitis 33.3% (placebo 9.4%) dizziness 26.7% (placebo 9.4%) NCT03496207 · Phase 2 · registry result, not featured evidence 0.3 mg/kg oedema peripheral 35.5% (placebo 15.6%) nasopharyngitis 32.3% (placebo 9.4%) diarrhoea 29% (placebo 15.6%) NCT03496207 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS235's landscape · Sotatercept's landscape